Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML ashpublications.org/blood/article/… . Germline variants seen in 13.6% (6.3% in clinically actionable genes), #DDX41 was most common with family hx of myeloid malignancies.

Exciting to see this prepublished online in @BloodJournal doi.org/10.1182/blood.… We found that the CD19 #CARTcell product type independently impacts outcomes in relapsed or refractory aggressive B-NHL. First CAR-T collaboration between Fred Hutch Cancer Center and OHSU News 😄

Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May sex in Washington DC Cancer Cell cell.com/cancer-cell/fu…

Nice poster on #CKD and outcomes of Flu/Mel allotransplant ⁦Monzr M. AlMalki, MD⁩ and team! CC: ⁦@ClarkRobinsonMD⁩ ⁦Nattawat Klomjit⁩ docs.google.com/viewer?url=htt…

Special thanks to Dr. Amanda Blackmon (City of Hope) for her presentation on "Innovations in Cell Therapy and HSCT" at #Tandem22.

Great honor to give the E. Donnall Thomas lecture at The 2022 Tandem Meeting

Out now in The Lancet Haematology via MD Anderson Cancer Center Leukemia | Outcomes of venetoclax combined with IC in #AML | VEN+IC👉 improved MRD-negative CR rates, transition to alloHSCT, and EFS compared to IC alone. bit.ly/3OCrBVn #leusm

📢Out now in AmericanJournalofHematology via MD Anderson Cancer Center #Leukemia👉 Extended follow up (median 20 mo.) with expanded enrollment (N=45) of FLAG-IDA-VEN in ND-AML | ORR: 98% | CRc: 89% | ⏫ MRD-neg CRc: 93%| 24-month OS 85% in ELN adv. risk w/o TP53 mut. Link👇 bit.ly/39yxbs7

Can you spot AML w/ inv(3)(q21q26) when you see it? 🕵🏻‍♀️It’s among the most aggressive forms of AML. Diagnostic clues: marked anemia+normal plt count, multilineage dysplasia +/- megakaryocytic hyperplasia and strikingly small megakaryocytes (red arrows) #hemepath 1/ 🧵 #leusm

New diagnosis of AML with normal karyotype with 👇 NGS results. All the driver mutations are present 🤯. What is driving the disease? We need #scDNAseq to decipher the #GameOfClones . Ferrell Lab Ross Levine #leusm

Published now @BloodCancerJNL 📢 Triplets (LIC+VEN+FLT3i) outperforms doublets (LIC+FLT3i) in frontline older/unfit FLT3m #AML. CR/CRi, MFC negativity, and the 2-year OS rates ➡ 93% vs. 70%, 83% vs. 38%, and 70% vs. 22% 👇 nature.com/articles/s4140… Musa Yilmaz, MD @DaverLeukemia

LIFE HISTORY of Investigator-initiated (sponsored) trial (IIT / IST) A🧵 Day 1. An idea. It came to you. Or came to your mentor. You saw something somewhere. Maybe it was ･ﾟ✧ or ASCO. You connected the dots. Month 1. You discuss it with your group. 1/19

We are excited to share the results of our cost effectiveness analysis of second line axi-cel in DLBCL published in Blood. Despite the high cost of CAR T, we demonstrate that second line axi-cel is cost effective if 5-year EFS is at least 26%. ashpublications.org/blood/article/…

It’s a beautiful fall day at the capitol with the ASH crew! Ready to #Fight4Hematology and #ConquerSCD! We’re here asking for: ⭐️NIH funding to $49 billion ⭐️#SCD CDC data collection to $10 million ⭐️#sicklecell Medicaid Demonstration Bill (S.3389 & H.R.6216)

#ASH22 News Daily Preview is in. Please check out Overview Natasha Szuber #DEI Juliana Perez Botero MD (she/her) 🌈 Maternal health Amanda Blackmon @ido amanam Scientific workshops Manni Mohyuddin Victoria A. Vardell, MD AI @D_Hermel ASH-a palooza Autumn Jeong MD @anupumakumar05 ASH

Excited for this years ASH meeting - maternal health and hematology sessions we are particularly excited for ashpublications.org/ashnewsdaily/n… Mikkael A. Sekeres MD, MS Allyson Pishko, MD MSCE Idoroenyi Amanam, MD Jane Apperley

Nice review on myelofibrosis current&upcoming Rx. Disheartens me however➡️BMT wrapped in 2 paragraphs when it’s the only modality that moves the needle for MF patients & no drugs “in the pipeline” alter natural history #mpnsm #bmtsm ⁦@BloodJournal⁩ ashpublications.org/blood/article/…

A new guideline from ASTCT Committee on Practice Guidelines reviews hematopoietic cell transplantation in the management of myelodysplastic syndrome: ow.ly/Cixy50MNmqY #openaccess #MMsm @ELShematology

So proud of Laura Dillon, PhD, FACMG stepping up to present at a clinical conference today #SOHO23 #SOHO2023 She also today received a ~$1M grant to accelerate the genomics on the MEASURE protocol clinicaltrials.gov/study/NCT05224… #WonderWoman #gettingstuffdone @TheBethesdaLabs ACMG Association for Molecular Pathology

Thank you to Amanda Blackmon City of Hope for the write-up of her talk today and the overview of what we are trying to do at NIH to move precision oncology forward for patients with AML in remission but at continued risk of relapse.